Overview
Camcevi Point-Lok Needle is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with advanced prostate cancer. The prescription includes a prefilled syringe with a separate needle protection device called the Point-Lok Needle. Camcevi is also known by its drug name, leuprolide.

How do I take it?
Prescribing information states that Camcevi Point-Lok Needle is given as a subcutaneous (under the skin) injection using a prefilled syringe with a Point-Lok Needle. It is typically administered once every six months. Camcevi Point-Lok Needle must be administered by a healthcare provider and should be used exactly as prescribed.

Side effects
Common side effects of Camcevi Point-Lok Needle include hot flushes, hypertension (high blood pressure), injection‑site reactions (e.g., discoloration, swelling, pain), fatigue, upper respiratory tract infections, musculoskeletal pain (bone or muscle pain), pain in extremity, arthralgia (joint pain), micturition urgency or nocturia (urinary urgency or frequency), and dizziness.

Rare but serious side effects may include a temporary worsening of prostate cancer symptoms early in treatment (tumor flare, which can cause bone pain, urinary obstruction, spinal cord compression) including possible paralysis; elevated blood sugar or new/worsening diabetes (hyperglycemia); increased risk of cardiovascular events (heart attack, sudden cardiac death, stroke); prolongation of the QT/QTc interval (a heart rhythm disturbance); seizures (convulsions); and severe skin reactions including serious cutaneous adverse reactions (SCARs) such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Camcevi Point-Lok Needle may also impair fertility and cause harm to an unborn baby if used in a person who could become pregnant. 

For more information about this treatment, visit:

Label: Camcevi — Leuprolide Injection, Emulsion — DailyMed